Mariano García-Arranz

Dr. Mariano García-Arranz

Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
DHDolores Herreros
Dolores Herreros
IPIsabel Pascual
Isabel Pascual
JPJosé Antonio Pascual
José Antonio Pascual
EDEmilio Del-Valle
Emilio Del-Valle
MPMaria Pascual
Maria Pascual
The feasibility and safety of stem cell-based therapy with expanded adipose-derived stem cells (ASCs) has been investigated in a phase I clinical trial. The present study was designed as a phase II multicenter, randomized controlled trial to further investigate the effectiveness and safety of ASCs in the treatment of complex perianal fistulas. Patients with complex perianal fistulas (cryptoglandular origin, n = 35; associated with Crohn's disease, n = 14) were randomly assigned to intralesional treatment with fibrin glue or fibrin glue plus 20 million ASCs. Fistula healing and quality of life (SF-12 questionnaire) were evaluated at eight weeks and one year. If healing was not seen at eight weeks, a second dose of fibrin glue or fibrin glue plus 40 million ASCs was administered. Fistula healing was observed in 17 (71 percent) of 24 patients who received ASCs in addition to fibrin glue compared with 4 (16 percent) of 25 patients who received fibrin glue alone (relative risk for healing, 4.43; confidence interval, 1.74-11.27); P < 0.001). The proportion of patients with healing was similar in Crohn's and non-Crohn's subgroups. ASCs were also more effective than fibrin glue alone in patients with a suprasphincteric fistulous tract (P = 0.001). Quality of life scores were higher in patients who received ASCs than in those who received fibrin glue alone. At one year follow-up, the recurrence rate in patients treated with ASCs was 17.6 percent. Both treatments were well tolerated. Administration of expanded ASCs (20 to 60 million cells) in combination with fibrin glue is an effective and safe treatment for complex perianal fistula and appears to achieve higher rates of healing than fibrin glue alone.

1 July 2012 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
MHM D Herreros
M D Herreros
MGMariano García-Arranz
Mariano García-Arranz
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara
PDP. De-La-Quintana
P. De-La-Quintana
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
Autologous adipose-derived stem cells may represent a novel approach for the management of complex fistula-in-ano. After successful phase I and II clinical trials, a phase III trial was performed to investigate the safety and efficacy. In this multicenter, randomized, single-blind, add-on clinical trial, 200 adult patients from 19 centers were randomly assigned to receive 20 million stem cells (group A, 64 patients), 20 million adipose-derived stem cells plus fibrin glue (group B, 60 patients), or fibrin glue (group C, 59 patients) after closure of the internal opening. Fistula healing was defined as reepithelization of the external opening and absence of collection >2 cm by MRI. If the fistula had not healed at 12 weeks, a second dose (40 million stem cells in groups A and B) was administered. Patients were evaluated at 24 to 26 weeks (primary end point) and at 1 year (long-term follow-up). All results are according to the "blinded evaluator" assessment. After 24 to 26 weeks, the healing rate was 39.1%, 43.3%, 37.3% in groups A, B, and C (p = 0.79). At 1 year, the healing rates were 57.1%, 52.4%, and 37.3 % (p = 0.13). On analysis of the subpopulation treated at the technique's pioneer center, healing rates were 54.55%, 83.33%, and 18.18%, at 24 to 26 weeks (p < 0.001). No SAEs were reported. In treatment of complex fistula-in-ano, a dose of 20 or 60 million adipose-derived stem cells alone or in combination with fibrin glue was considered a safe treatment, achieving healing rates of approximately 40% at 6 months and of more than 50% at 1-year follow-up. It was equivalent to fibrin glue alone. No statistically significant differences were found when the 3 groups where compared. www.clinicaltrials.gov, identifier NCT00475410; Sponsor, Cellerix SA.

13 January 2010 in Cancer Research
Verified
Journal Article
Closed access
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
CDCarolina Domínguez
Carolina Domínguez
MGMariano García-Arranz
Mariano García-Arranz
PAPhillipe Anker
Phillipe Anker
MSMaurice Stroun
Maurice Stroun
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
It has been proposed that cell-free nucleic acids in the plasma participate in tumorigenesis and the development of metastases via transfection-like uptake of such nucleic acids by susceptible cells. This putative phenomenon is tentatively referred to as “genometastasis.” In the present study, we examined the effects on cultured cells of plasma from healthy individuals and from patients with colon cancer. Cultures of NIH-3T3 cells and human adipose-derived stem cells (hASC) were supplemented with samples of plasma from patients with K-ras–mutated colorectal tumors or from healthy subjects using two different protocols: direct addition of plasma to cultures in standard plates and addition in the absence of contact between plasma and cells, which were separated by a membrane with 0.4-μm pores. In plasma-treated hASCs, no K-ras–mutated sequences were detected by real-time PCR. In contrast, in most cultures of plasma-treated NIH-3T3 cells (murine cells), the transfer of human DNA occurred, as verified by the detection of human K-ras sequences, p53 sequences, and β-globin–encoding sequences. Moreover, NIH-3T3 cells that had been cultured with plasma from patients with colon cancer were oncogenically transformed, as shown by the development of carcinomas in nonobese diabetic–severe combined immunodeficient mice after the injection of such cells. Microscopic analysis of membranes that had separated plasma from cultured cells confirmed the complete absence of cells in the plasma. We only observed noncell particles, having diameters of <0.4 μm. Our results indicate that plasma from cancer patients is able to transform cultured cells oncogenically, supporting the previously proposed hypothesis of genometastasis. Cancer Res; 70(2); 560–7

9 November 2011 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
Héctor GuadalajaraHéctor Guadalajara
Héctor Guadalajara
DHDolores Herreros
Dolores Herreros
PDPaloma De-La-Quintana
Paloma De-La-Quintana
JTJacobo Trebol
Jacobo Trebol
MGMariano García-Arranz
Mariano García-Arranz
Damián García-OlmoDamián García-Olmo
Damián García-Olmo

12 August 2008 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
DHDolores Herreros
Dolores Herreros
MPMaria Pascual
Maria Pascual
IPIsabel Pascual
Isabel Pascual
PDPaloma De-La-Quintana
Paloma De-La-Quintana
MGMariano García-Arranz
Mariano García-Arranz

11 August 2008 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
Damián García-OlmoDamián García-Olmo
Damián García-Olmo
MGMariano García-Arranz
Mariano García-Arranz
DHDolores Herreros
Dolores Herreros
Background: Complex perianal fistulising disease is a distressing condition. In patients without Crohn's disease, surgery is the mainstay treatment but faecal incontinence and recurrence are high. Infliximab is used in Crohn's patients but not all respond to therapy. Objective: After an evaluation of the current treatment options, we discuss studies of adipose-derived stem cell (ASC) therapy, a novel approach for treating complex perianal fistulas. Methods: ASCs are obtained from a liposuction procedure and a subsequent expansion process. They are administered according to a strict protocol which involves infusion of the cells into the target lesion along with fibrin glue. Results/conclusions: A Phase IIb study comparing ASC and fibrin glue therapy with fibrin glue therapy alone showed that ASCs were effective at inducing healing in complex perianal fistulas.